Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of “Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average rating of “Buy” from the ten analysts that are covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.8889.

CMPX has been the topic of a number of research reports. Raymond James Financial raised Compass Therapeutics to an “outperform” rating and set a $9.00 price objective on the stock in a research note on Tuesday, July 1st. Guggenheim raised their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, August 12th.

Compass Therapeutics Stock Down 1.7%

Shares of CMPX stock opened at $3.37 on Friday. The company’s fifty day simple moving average is $2.98 and its two-hundred day simple moving average is $2.48. Compass Therapeutics has a 52 week low of $1.27 and a 52 week high of $4.08. The stock has a market cap of $466.00 million, a P/E ratio of -7.49 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CMPX. Creative Planning purchased a new position in Compass Therapeutics in the second quarter worth about $30,000. Tower Research Capital LLC TRC boosted its holdings in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares during the period. Strs Ohio bought a new position in shares of Compass Therapeutics during the 1st quarter valued at approximately $34,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics during the 4th quarter valued at $27,000. Finally, Mariner LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at $30,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.